FDA adverse event data put semaglutide among the top five drugs tied to gallstones and cholecystitis, and pharmacists are urged to watch for early signs.
Recap by typeshit. Full story at Pharmacy Times.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
About 180 people will get MRI scans while making food and money choices through March 2027. Noom is funding the work led by neuroscientist Michael Platt.
There's no appeal under the Bridge, but prescribers can resubmit the prior authorization form. The group explains who counts as Part D eligible instead.
Loading…